Our Pipeline

molecule

Our Pipeline

Orphan Technologies is focused on developing and commercializing innovative treatments for patients with rare disease so they can live a higher quality of life.

Orphan Technologies is dedicated to helping patients control their homocysteine levels. Our lead program OT-58, is an enzyme therapy that has the opportunity to address the underlying CBS deficit for patients living with homocystinuria.